Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC) - Episode 9

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

, , ,

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
EP. 5: Management of Borderline Resectable NSCLC
EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations
EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
Now Viewing
EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

How do you select patients with unresectable stage 3 NSCLC forsequential vs concurrent chemoradiotherapy (sCRTandcCRT)? How do available data help inform your treatment decision?